209 related articles for article (PubMed ID: 24180294)
1. Nonmetabolic complications of continuous subcutaneous insulin infusion: a patient survey.
Pickup JC; Yemane N; Brackenridge A; Pender S
Diabetes Technol Ther; 2014 Mar; 16(3):145-9. PubMed ID: 24180294
[TBL] [Abstract][Full Text] [Related]
2. Perceptions and experiences of adult patients with type 1 diabetes using continuous subcutaneous insulin infusion therapy: Results of an online survey.
Taleb N; Messier V; Ott-Braschi S; Ardilouze JL; Rabasa-Lhoret R
Diabetes Res Clin Pract; 2018 Oct; 144():42-50. PubMed ID: 30077691
[TBL] [Abstract][Full Text] [Related]
3. Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents.
Conwell LS; Pope E; Artiles AM; Mohanta A; Daneman A; Daneman D
J Pediatr; 2008 May; 152(5):622-8. PubMed ID: 18410763
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting.
Alamoudi R; Alsubaiee M; Alqarni A; Saleh Y; Aljaser S; Salam A; Eledrisi M
Diabetes Technol Ther; 2017 Jun; 19(6):349-354. PubMed ID: 28296467
[TBL] [Abstract][Full Text] [Related]
5. Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation.
Blair JC; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes DA; Gamble C;
BMJ; 2019 Apr; 365():l1226. PubMed ID: 30944112
[TBL] [Abstract][Full Text] [Related]
6. Treatment satisfaction and quality of life for an integrated continuous glucose monitoring/insulin pump system compared to self-monitoring plus an insulin pump.
Rubin RR; Peyrot M
J Diabetes Sci Technol; 2009 Nov; 3(6):1402-10. PubMed ID: 20144395
[TBL] [Abstract][Full Text] [Related]
7. Continuous subcutaneous insulin infusion therapy: A primer on insulin pumps.
Potti LG; Haines ST
J Am Pharm Assoc (2003); 2009; 49(1):e1-13; quiz e14-7. PubMed ID: 19196588
[TBL] [Abstract][Full Text] [Related]
8. Long-term benefits of continuous subcutaneous insulin infusion in children with Type 1 diabetes: a 4-year follow-up.
Sulli N; Shashaj B
Diabet Med; 2006 Aug; 23(8):900-6. PubMed ID: 16911629
[TBL] [Abstract][Full Text] [Related]
9. [The use of continuous subcutaneous insulin infusion (CSII) with personal insulin pumps in the treatment of children and adolescents with diabetes type 1].
Jarosz-Chobot P
Wiad Lek; 2004; 57(5-6):263-6. PubMed ID: 15518073
[TBL] [Abstract][Full Text] [Related]
10. Frequency of dermatological side effects of continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes.
Binder E; Lange O; Edlinger M; Meraner D; Abt D; Moser C; Steichen E; Hofer SE
Exp Clin Endocrinol Diabetes; 2015 Apr; 123(4):260-4. PubMed ID: 25607337
[TBL] [Abstract][Full Text] [Related]
11. Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial.
Beck RW; Riddlesworth TD; Ruedy KJ; Kollman C; Ahmann AJ; Bergenstal RM; Bhargava A; Bode BW; Haller S; Kruger DF; McGill JB; Polonsky W; Price D; Toschi E;
Lancet Diabetes Endocrinol; 2017 Sep; 5(9):700-708. PubMed ID: 28711468
[TBL] [Abstract][Full Text] [Related]
12. Family perceptions of insulin pump adverse events in children and adolescents.
Wheeler BJ; Donaghue KC; Heels K; Ambler GR
Diabetes Technol Ther; 2014 Apr; 16(4):204-7. PubMed ID: 24313790
[TBL] [Abstract][Full Text] [Related]
13. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
[TBL] [Abstract][Full Text] [Related]
14. Continuous subcutaneous insulin infusion (CSII) pumps.
Valla V
Adv Exp Med Biol; 2012; 771():414-9. PubMed ID: 23393693
[TBL] [Abstract][Full Text] [Related]
15. Weight in adolescents with type 1 diabetes mellitus during continuous subcutaneous insulin infusion (CSII) therapy.
Raile K; Noelle V; Landgraf R; Schwarz HP
J Pediatr Endocrinol Metab; 2002 May; 15(5):607-12. PubMed ID: 12014519
[TBL] [Abstract][Full Text] [Related]
16. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
Bode BW
Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
[TBL] [Abstract][Full Text] [Related]
17. Impact of Medicare Continuous Subcutaneous Insulin Infusion Policies in Patients With Type 1 Diabetes.
Argento NB; Liu J; Hughes AS; McAuliffe-Fogarty AH
J Diabetes Sci Technol; 2020 Mar; 14(2):257-261. PubMed ID: 30931609
[TBL] [Abstract][Full Text] [Related]
18. Insulin pump-associated adverse events are common, but not associated with glycemic control, socio-economic status, or pump/infusion set type.
Ross P; Gray AR; Milburn J; Kumarasamy IM; Wu F; Farrand S; Armishaw J; Wiltshire E; Rayns J; Tomlinson P; Wheeler BJ
Acta Diabetol; 2016 Dec; 53(6):991-998. PubMed ID: 27585938
[TBL] [Abstract][Full Text] [Related]
19. Differences in depression, treatment satisfaction and injection behaviour in adults with type 1 diabetes and different degrees of lipohypertrophy.
Hernar I; Haltbakk J; Broström A
J Clin Nurs; 2017 Dec; 26(23-24):4583-4596. PubMed ID: 28295770
[TBL] [Abstract][Full Text] [Related]
20. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group.
Heinemann L; Fleming GA; Petrie JR; Holl RW; Bergenstal RM; Peters AL
Diabetologia; 2015 May; 58(5):862-70. PubMed ID: 25784563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
